.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,770,582

« Back to Dashboard

Details for Patent: 5,770,582

Title: Pharmaceutical compositions containing deoxyribonucleosides for wound healing
Abstract:The invention relates to compositions comprising 2'-deoxyribonucleosides. The invention also relates to methods of accelerating the healing of wounds, abrasions, cuts, incisions, and superficial burns induced by heat, sunlight, chemical agents, or infections, and methods for ameliorating the effects of aging of the epidermal tissues comprising administering the compositions of the present invention to an animal.
Inventor(s): von Borstel; Reid Warren (Kensington, MD), Bamat; Michael Kevin (Chevy Chase, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Filing Date:Apr 10, 1995
Application Number:08/419,767
Claims:1. A pharmaceutical composition consisting essentially of:

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine, wherein each of said 2'-deoxycytidine and 2'-deoxyguanosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(c) a pharmaceutically acceptable carrier, said carrier being adapted for local or topical administration,

wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

2. A pharmaceutical composition consisting essentially of,

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine,

(c) 2'-deoxyadenosine, wherein each of said 2'-deoxycytidine, 2'-deoxyguanosine and 2'-deoxyadenosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(d) a pharmaceutically acceptable carrier, said carrier being adapted for local or topical administration,

wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

3. A pharmaceutical composition consisting essentially of,

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine,

(c) 2'-deoxythymidine, wherein each of said 2'-deoxycytidine, 2'-deoxyguanosine and 2'-deoxythymidine are in the free form or a 3', or 5' phosphate, or 3',5' phosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(d) a pharmaceutically acceptable carrier, said carrier being adapted for local or topical administration,

wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

4. A pharmaceutical composition consisting essentially of,

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine

(c) 2'-deoxythymidine

(d) 2'-deoxyadenosine, wherein each of said 2'-deoxycytidine, 2'-deoxyguanosine, 2'-deoxythymidine and 2'-deoxyadenosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(e) a pharmaceutically acceptable carrier, said carrier being adapted for local or topical administration,

wherein said composition is in a form selected from the group consisting of an ointment gel, cream, lotion and paste.

5. A pharmaceutical composition as recited in claim 1, 2, 3 or 4 wherein each of said components (a) and (b) is present in from 25 to 75 percent of said active agent.

6. A pharmaceutical composition as in claim 1, 2, 3 or 4, wherein each nucleoside is present as a 3' or 5' phosphate or a 3',5' diphosphate ester derivative.

7. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said composition is an ointment.

8. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said composition is a gel.

9. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said composition is a cream.

10. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said composition is a lotion.

11. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said composition is a paste.

12. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is selected from the group consisting of alginate, carboxymethylcellulose, gum xanthan, methylcellulose, agarose, pectins, gelatin, collagen, vegetable oil, mineral oil, stearic acid, stearyl alcohol, petrolatum, polyethylene glycol, polysorbate, polylactate, polyglycolate, polyanhydride, phospholipids, and polyvinylpyrrolidone.

13. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is alginate.

14. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is carboxymethylcellulose.

15. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is methylcellulose.

16. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is a colloidal dispersion.

17. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is a mucilaginous dispersion.

18. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is a demulcent base.

19. A pharmaceutical composition as in claim 1, 2, 3 or 4 wherein said carrier is liposomes.

20. A pharmaceutical composition comprising:

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine, wherein each of said 2'-deoxycytidine and 2'-deoxyguanosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(c) an antibiotic.

21. A composition as in claim 20 wherein said antibiotic is selected from the group consisting of quaternary ammonium compounds, bacitracin, neomycin and polymyxin.

22. A composition as in claim 20 wherein said composition is a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

23. A pharmaceutical composition comprising:

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine, wherein each of said 2'- deoxycytidine and 2'-deoxyguanosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(c) an antiviral.

24. A composition as in claim 23 wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

25. A pharmaceutical composition comprising:

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine, wherein each of said 2'-deoxycytidine and 2'-deoxyguanosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(c) an anti-inflammatory agent.

26. A composition as in claim 25 wherein said anti-inflammatory agent is a corticosteroid.

27. A composition as in claim 25 wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

28. A pharmaceutical composition comprising:

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine, wherein each of said 2'-deoxycytidine and 2'-deoxyguanosine are in the free form or a 3', or 5' phosphate, or 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(c) a sunscreen.

29. A composition as in claim 28 wherein said composition is in a form selected from the group consisting of an ointment, gel, cream, lotion, and paste.

30. A pharmaceutical composition as in claim 28 wherein said sunscreen is PABA or an ester of PABA, and wherein said composition is a suntan lotion.

31. A pharmaceutical composition as in claim 28 further comprising a pharmaceutically acceptable carrier selected from the group consisting of alginate, carboxymethylcellulose, gum xanthan, methylcellulose, agarose, pectin, gelatin, collagen, vegetable oil, mineral oil, stearic acid, stearyl alcohol, petrolatum, polyethylene glycol, polysorbate, polyactate, polyglycolate, polyanhydride, phospholipid, and polyvinylpyrrolidine.

32. A pharmaceutical composition as in claim 31 wherein said carrier is alginate.

33. A pharmaceutical composition as in claim 31 wherein said carrier is carboxymethylcellulose.

34. A pharmaceutical composition as in claim 31 wherein said carrier is methylcellulose.

35. A pharmaceutical composition as in claim 28 wherein said composition is in the form of a colloidal dispersion.

36. A pharmaceutical composition as in claim 28 wherein said composition is in the form of a mucilaginous dispersion.

37. A pharmaceutical composition as in claim 28 wherein said composition is in the form of a demulcent base.

38. A pharmaceutical composition as in claim 28 wherein said composition is in the form of liposomes.

39. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising a compound selected from the group consisting of allantoin, retinoic acid, aloe vera, glycine, vitamin A, vitamin B, vitamin C, vitamin E, comfrey root preparation platelet, platelet extract, ribonucleoside, collagen, proline, lysine, elastin, fibronectin, glycosaminoglycan, polyamine, angiogenic factor, zinc, sucrose, somatomedin, lamin, EGF, IGF, PDGF, FGF, EDGF, TGF, CDGF, MDGF, and NGF.

40. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising allantoin.

41. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising retinoic acid.

42. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising aloe vera.

43. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising vitamin C.

44. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising vitamin E.

45. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising a ribonucleoside.

46. A pharmaceutical composition as in claim 1, 2, 3, 4 or 28 further comprising zinc.

47. A pharmaceutical composition as in claim 28 further comprising 2'-deoxyadenosine in the free form or a 3', or 5' phosphate, or a 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salt thereof.

48. A pharmaceutical composition as in claim 28 further comprising 2'-deoxythymidine in the free form or a 3', or 5' phosphate, or a 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salt thereof.

49. A pharmaceutical composition as in claim 47 further comprising 2'-deoxythymidine in the free form or a 3', or 5' phosphate, or a 3',5' diphosphate ester derivative thereof, or the pharmaceutically acceptable salt thereof.

50. A dressing impregnated with the composition of claim 1, 2, 3 or 4.

51. A bandage impregnated with the composition of claim 1, 2, 3 or 4.

52. Artificial skin containing the composition of claim 1, 2, 3 or 4.

53. A pharmaceutical composition as in claim 1, 2, 3 or 4, wherein each nucleoside is present in the free form.

54. A pharmaceutical composition consisting essentially of,

(a) from 10 to 90 percent by mol 2'-deoxycytidine,

(b) from 90 to 10 percent by mol 2'-deoxyguanosine

(c) 2'-deoxythymidine

(d) 2'-deoxyadenosine, wherein each of said 2'-deoxycytidine, 2'-deoxyguanosine, 2'-deoxythymidine and 2'-deoxyadenosine are in the free form or a 3', or 5' phosphate, or 3',5' phosphate ester derivative thereof, or the pharmaceutically acceptable salts thereof, and

(e) a pharmaceutically acceptable carrier, said carrier being adapted for local or topical administration,

wherein said composition is a dusting powder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc